Metabolic sarcopenia in the era of incretin-based therapy: a narrative review of mitochondrial determinants of muscle quality and emerging therapeutic strategies.
A therapeutic framework that combines GLP-1-based metabolic disease management, muscle health, and mitochondrial quality control is proposed that combines incretin pharmacotherapy with resistance exercise, protein and micronutrient support, monitoring of body composition and function, and investigational mitochondria-t...